80%Confidence
0Views
FDASource
2026-04-12Date
Summary
Chiesi USA's Class II recall for CUROSURF due to lack of sterility assurance raises concerns about its neonatal respiratory drug supply, potentially affecting hospital formularies and patient care. This could temporarily benefit competitors in the surfactant market while Chiesi addresses the manufacturing issue.
Actionable: Assess competitive dynamics in the neonatal surfactant market for potential short-term opportunities as Chiesi manages this recall.
AI Confidence: 80%
Data Points
firmChiesi USA, Inc.
classificationClass II
statusOngoing
distributionNationwide within the United States
productCUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now